SCHEMBL12337202

SCHEMBL12337202

CC(C)(C)OC(=O)N1CCc2cccc(OS(=O)(=O)C(F)(F)F)c2[C@@H]1c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.48
CYP2D6 P10635 3/20 0.45
NR1H2 P55055 2/20 0.42
NR1H3 Q13133 2/20 0.42
HTR1D P28221 1/20 0.41
DRD3 P35462 1/20 0.41
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
CHRM3 P20309 2/20 0.39
CACNA1F O60840 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM5 P08912 1/20 0.39
CHRM1 P11229 1/20 0.39
KCNE1 P15382 1/20 0.39
KCNQ1 P51787 1/20 0.39
CACNA1D Q01668 1/20 0.39
KCNH2 Q12809 1/20 0.39
CACNA1S Q13698 1/20 0.39
CACNA1C Q13936 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2793111 0.88 DRD2 (0.48) DRD2CYP2D6HTR1DDRD3ESR1
SCHEMBL12311999 0.81 DRD2 (0.61) DRD2HTR1DDRD3
SCHEMBL2796138 0.79 CYP2D6 (0.45) DRD2CYP2D6NR1H2NR1H3CHRM3
SCHEMBL12337795 0.78 CHRM3 (0.41) DRD2CYP2D6NR1H2NR1H3CHRM3
SCHEMBL12159030 0.77 DRD2 (0.43) DRD2NR1H2NR1H3HTR1DDRD3
SCHEMBL25142600 0.76 CHRM3 (0.58) CYP2D6CHRM3CACNA1FCHRM2CHRM4
SCHEMBL1567179 0.76 CHRM3 (0.58) CYP2D6CHRM3CACNA1FCHRM2CHRM4
SCHEMBL506250 0.75 DRD2 (0.47) DRD2NR1H2HTR1DDRD3ESR2
SCHEMBL29561886 0.75 TRPV1 (0.47) DRD2HTR1DDRD3CHRM3KCNH2
SCHEMBL7676137 0.74 ESR2 (0.46) DRD2NR1H2HTR1DDRD3ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263607-B2 1-substituted tetrahydroisoquinoline compound ASTELLAS PHARMA INC. (JP) 2012-09-11 US disclosed
US-20100168154-A1 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND ASTELLAS PHARMA INC. (JP) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168154-A1 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND CACNA1S, CACNA1E, CACNA1B DRD2 202/4885CYP2D6 834/4885NR1H2 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.